NDAINTRAVENOUSPOWDERPriority Review
Approved
Sep 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
IDAMYCIN (idarubicin hydrochloride) by Pfizer is dna, inhibiting nucleic acid synthesis, inhibiting topoisomerase ii activity, and producing dna-damaging free radicals. First approved in 1990.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IDAMYCIN (idarubicin hydrochloride) is a small-molecule anthracycline chemotherapeutic agent approved in 1990 for acute myeloid leukemia (AML). It works by intercalating into DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and generating DNA-damaging free radicals to kill rapidly dividing leukemic cells.
LOE Approaching
As a legacy anthracycline approaching loss of exclusivity, IDAMYCIN likely operates with a stable but shrinking commercial team, with focus shifting toward lifecycle management and cost containment rather than growth initiatives.
Mechanism of Action
DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IDAMYCIN offers limited career growth in a mature, declining product with zero linked job openings and competitive pressure eroding market position. Roles focus on defending market share, managing generic transition, and maximizing profitability rather than innovation or expansion.
Brand ManagerSales Representative
Worked on IDAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.